Millennium's bug: India scorns at Velcade review petition
This article was originally published in Scrip
Executive Summary
India's Intellectual Property Appellate Board (IPAB) has dismissed Takeda subsidiary Millennium Pharmaceuticals' review petition concerning its multiple myeloma drug ,Velcade (bortezomib), chiding the firm for trying to mask its efforts to get a rehearing in the case via the petition.